{"name":"Sosei","slug":"sosei","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AD 237","genericName":"AD 237","slug":"ad-237","indication":"Advanced solid tumors (Phase 2 development)","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"AD 337","genericName":"AD 337","slug":"ad-337","indication":"Relapsing multiple sclerosis","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"AD 452","genericName":"AD 452","slug":"ad-452","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"AD 237","genericName":"AD 237","slug":"ad-237","phase":"phase_2","mechanism":"AD 237 is a selective antagonist of the adenosine A2A receptor that blocks immunosuppressive signaling in the tumor microenvironment.","indications":["Advanced solid tumors (Phase 2 development)"],"catalyst":""},{"name":"AD 337","genericName":"AD 337","slug":"ad-337","phase":"phase_2","mechanism":"AD 337 is a small molecule targeting the S1P1 receptor.","indications":["Relapsing multiple sclerosis"],"catalyst":""},{"name":"AD 452","genericName":"AD 452","slug":"ad-452","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOa0poOXpWNEYwTXZNaTB2SzRlNjNNMWhyUmMtVDN4UGhabFQtOExESkQ2Q3ZnS1V4aVAyQUVQWl9XUXlweEt1VDM1ZExVZjVYaGJVVGdVbV9TSWw3a3BpOGdUUllGamRSNGMzdFhIQWhudF9BbUtyb2xFdWFkTS02amlNTFhzYzZIU3NEUXBRa2dvUTVwWXJ5WE9wUk9wU1QxUnpZV0FyRE5vSVdKR0dR?oc=5","date":"2026-04-01","type":"deal","source":"Business Weekly","summary":"Cambridge research leads to $7.8bn mega-deal as Lilly swoops for Centessa - Business Weekly","headline":"Cambridge research leads to $7.8bn mega-deal as Lilly swoops for Centessa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQM1VRRENNMmNOUjNFMjU3V1U4MFhMT1VIN2F1NVM1ZjltZzJYUlRDRzdocVNkNGtiaG92eXJnR25LcVJFYnBFc3dVZFpSSVN0bzMxN2dLT1ZLR09Ld0ZSLTgxdnMxUVhfYnA2QWFDMkJ0N2t3Vmxyd2xfOEdZa2dqNVdsUnpZQVdwT05UeWlQbTdSdkNpLTl2Q3F0NDcxRVZ5LWl0U2VRaVNkbkJ1aVgwYjdYbWt2Y0lBWW55UA?oc=5","date":"2026-04-01","type":"deal","source":"TipRanks","summary":"Lilly’s Centessa Deal Highlights Nxera Pharma’s GPCR Platform Strength - TipRanks","headline":"Lilly’s Centessa Deal Highlights Nxera Pharma’s GPCR Platform Strength","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNbHpITFZBMnhpUy03TktZWV96NHhJRDhpamRVcV8yRzJFT09zbGtKck9vVXJ0cFg1ZmRqUG9TVXhRR2lZdkpac2ctN3ZwX1hYRFBteDEzMHY0MXlUQXR5cmp3aGpDQW53eEhrMkNHdEo2Q2thcF9rVm01OUZCYU1tRlJlWG1ZNDlncGoxS1VNOUkyZlA2Z2tjdFpTZmt5OFQ5UWdzdGJjN0J3TUxQenZzTmFIOHFRdDdlQXpr?oc=5","date":"2026-03-25","type":"pipeline","source":"TipRanks","summary":"Nxera Pharma Refreshes Board While Maintaining Core Leadership Team - TipRanks","headline":"Nxera Pharma Refreshes Board While Maintaining Core Leadership Team","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPbUkwcERGWm5DUWg0a2U2MjN3ZlR1VGJ3UW51Y0dHVlMzMlREUy1JNXU3MXRWZUpVdkJoSVVPcUV1blpxNnNISTRvUnFtdUp5amNrbXBmRmppVVJrTHhsb2Q2dGl4RnRUeURGUWdTV2FnenB0WEVUOTVmSExZcGJFdnBYZGpGUmdnQlRqX1VmOHRpbEV0VnJQR05md2dISDFrSVhUZw?oc=5","date":"2025-12-19","type":"trial","source":"Fierce Biotech","summary":"Boehringer walks away from Nxera's phase 2-ready schizophrenia program - Fierce Biotech","headline":"Boehringer walks away from Nxera's phase 2-ready schizophrenia program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPMVJLODllNlZDMnJKYWRMRDJ3Q0lHVzkwQi1yS1ZqMmFLbTNKQ3F5NGRieTNNdTEzOVRqZlVDODhhVmVpdWd4ME5scno0Yy1kWnZVRVg3MUhZNVZ6bVJvNm8xemsxZUVIcVd6UndOSEduWXZPMDF0M0xfYUhSOGxfSVFIX19RSjFkU1NVX0oyWlk?oc=5","date":"2025-11-18","type":"earnings","source":"BioSpace","summary":"Nxera’s Quest for Profitability Claims 15% of Workforce - BioSpace","headline":"Nxera’s Quest for Profitability Claims 15% of Workforce","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQaG9NMkk1VFhIYUVvQWwzeGRlRGx5cG56NEhkeGdxaGpfTEtTUXY0dlE2cDdUMno0aDR4OUVYems3MlFGSnF1Q0ZIYTVOTDZXZHVDWVF0UFBEdVBTY2tMTXQyLVA3TWI5VjZ1MnVpZzVhWGRuMC1EWXNIazFOSFFVdUNPV0o0WEpDSC1wWXREQnlhalhOdDViTXN2RjZfR3gtYnY0?oc=5","date":"2025-11-17","type":"earnings","source":"Fierce Biotech","summary":"Nxera lays off 15% of staff, pivots pipeline focus in profitability push - Fierce Biotech","headline":"Nxera lays off 15% of staff, pivots pipeline focus in profitability push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNMlNwc0ZoUFhuSDdza2ZSMDBMdC15UXBVREtMNlVoNXVIZWwyRnRNYmtmZ2l1VkpJRmJZN0w5cUU0RUY5WG8xbEFKbkxZZGo5bXV6UlVlRGwtY25qVzJQVDlpQnVIQ05OVWgyR1VVNmdqVWkxbmFYUEhfQXUyemZWOEFrTlJmeWNxUldqaWdCZG1SbTJ3VlphMjVMck9VX2NrWTdXV1NLS3BSSTdKTnlIOU5jSEt6TFMyemJzcmVxMnQxXzVYcDVoLUxBclVOOXI0QlE?oc=5","date":"2025-08-11","type":"pipeline","source":"PharmTech.com","summary":"Nxera’s New GLP-1 and GPCR-Targeted Drug Programs Aim to Advance Obesity and Metabolic Disorder Therapies - PharmTech.com","headline":"Nxera’s New GLP-1 and GPCR-Targeted Drug Programs Aim to Advance Obesity and Metabolic Disorder Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBtWkNTcXJGcmdJcEpURXFsUnJVMWt2Zk1aT3lMQ3Z4Z3FPOUNkS1B1RVZaejVGOWFHZThDY1ZnamliRmhjQUQ3M3VrcUlXanBXa1FB?oc=5","date":"2025-08-05","type":"pipeline","source":"FirstWord Pharma","summary":"As Pfizer pulls back on obesity asset, Nxera unveils brand new pipeline - FirstWord Pharma","headline":"As Pfizer pulls back on obesity asset, Nxera unveils brand new pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxQaTBYMlFSMTNPalhqc3NvSUQ0TGl4aGpRZm1aSmJSWUM2d3pURE5WOXVVZjdZTnhvemZaWlY3OGtiWHQ1RlJVaDFhYTMwcTNzQ3owaW1QU0RYOTNTU19QNXhDeHJhWExkQjNpTExoMlZyTmtBbTdCLUhMZV9rREtBWDV5MGxkbmsxSEppdUg2Q1dwT1lKS1huOVFKLWJydzllbFFzR0JlcEVWZnRWeWk2SXdpZjlqQWtpSEtYQTRjSHpuX1o2aXZIRnJTSDJPaG9tS3pMRTNUTElFYjhOOEw5SFlfTEJEZDAteFRySU12V2xsN3prSm92Mm9oMy1KekNYZERFMVNsZGE0QQ?oc=5","date":"2024-11-08","type":"pipeline","source":"Boehringer Ingelheim","summary":"Boehringer Ingelheim and Nxera Pharma (formerly Sosei Heptares), operating from Basel, Switzerland, collaborate to develop first-in-class treatments targeting all symptoms of schizophrenia - Boehringe","headline":"Boehringer Ingelheim and Nxera Pharma (formerly Sosei Heptares), operating from Basel, Switzerland, collaborate to devel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPMzRYUDBwN25nSU5MM0dBRHF6dEd2bWJHZVhZNjVtZ0gwbGk3Q0tZS0owMl9hYktwNUcyVDY1Z3YyTFV4dmIxOE5hVkxFcy05cTZLak9fUlJFYmNuZTdlODJNcHBpRTJ0bXVBSzBxV0NfUmhrRGFQRy1IVWRMZUJxelIxU3N1WlZPNmV6Sw?oc=5","date":"2024-02-16","type":"pipeline","source":"Fierce Pharma","summary":"Sosei ushers in new era with Nxera Pharma name change - Fierce Pharma","headline":"Sosei ushers in new era with Nxera Pharma name change","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOM0dHbTBYa2lmbW1UdFJsVFM1NlIyNG80R0xHN0FaYlU2ZGRhbi1rSy1JY19Sb19lRmp6QU80TmVVcmw4QkswRnJIaWFTb0Y3MjB1S1d6MFpqSVNqU0E5YUFfeWpaNGQ3bDdLSVJBTjlBOE16bXBQWGFuUFhWZG15NlhFM3poQnF4QS1xZmVhNElYb1FQZWx5ZEpHLV9QemFnXzFmRDBYVmVJWkNzOGtKdmxTaURwUQ?oc=5","date":"2023-10-31","type":"deal","source":"Pharmaceutical Technology","summary":"Sosei Heptares hits discovery milestone in GPCR deal with Genentech - Pharmaceutical Technology","headline":"Sosei Heptares hits discovery milestone in GPCR deal with Genentech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxQUG53N2FiaXRPYWZRaHczaEFHM0doV3Zka2ZPcGxaVndnQ3hOeHVpMXBPbldabTlMSGhCX0VQanpmMkRuUmlLczZhMnh0djY1aUt3X3QxWFc2X3JQXzRmV1VfWXVwRlhBM2xpU2ItSHUwVGNQZXBmSklZNUVDeUJBd0RQaDNQXzVMU19aaElnVW5USktUb3c1SENJaUJRVVNOWUxLdFFwWU5BdGo4S0JPVHNGYThrQ3Z3bW0zZm5xX000RC13OVZjU1ZwVUpKbXJlZ25V?oc=5","date":"2023-07-20","type":"deal","source":"orrick.com","summary":"‘Truly Transformational:’ Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China) - orrick.com","headline":"‘Truly Transformational:’ Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China)","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}